Latest News

The epidemiology, inflammatory pathophysiology, diagnosis, and treatment of diabetic macular edema are discussed during Inflammatory Eye Disease Week.

Himani Goyal, MD, reviews a patient case and discusses what a multispecialty group is seeing in practice.

CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.

Eleonora Lad, MD, PhD, Dimitra Skondra, MD, PhD, and John Kitchens, MD, point to structure and function, diet and the gut, and the future of reimbursement.

Spectacle lenses with highly aspherical lenslets are safe and effective for reducing myopia progression in US children.

CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.

Enrollment in the licaminlimab trial closed above target, with two-thirds of 176 patients carrying a TNFR1 variant associated with stronger treatment response. Topline data are expected around year-end 2026.

Prevent Blindness marks IED Week, October 19 to 25, as new therapies and pivotal trials reshape care for uveitis and thyroid eye disease.

Second phase 3 trial of Duravyu misses wet AMD noninferiority end point; EyePoint cuts 53% of staff to focus on DME.

Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.

Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.

Jordi Monés, MD, PhD, explains why RP and Stargardt data support testing son-vec to restore vision in advanced GA.

Two phase 1 OSPREY cohorts of intravitreal STK-002 for ADOA are dosed; first safety and efficacy data are expected by mid-2027.